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Approximately 10–80%of patients withCystic Fibrosis (CF) have vitaminD deficiency. Obtaining therapeutic vitaminD levels has been a challenge
for CF care providers using current recommended high-dose oral ergocalciferol (400,000 IU over 2 months). The objective of this study was to evaluate
the safety and efficacy of a 2-week, very high dose ergocalciferol (700,000 IU over 14 days) repletion strategy in children and young adults with CF.
As part of a quality improvement initiative, a prospective cohort study was performed from January through May 2007. Phase I included
identifying individuals with CF who were subtherapeutic in 25-OH D. In phase II, 50,000 IU of ergocalciferol was prescribed for a 14 day term
and administered daily. During phase III, a post treatment 25-OH D level was obtained to determine improvement. Baseline demographics and
clinical characteristics were obtained at study entry. Stratification of the post 25-OHD levels was defined.
Eighteen individuals with CF participated in the study. The mean age was 17±5 years (range 6–25 years). One hundred percent were
pancreatic insufficient and required pancreatic enzyme replacement. All 18 had 25-OHD levels less than 30 ng/mL pre-treatment.
Seventeen of the 18 (94%) participants became therapeutic in the 2-week interval. No patients had values considered high abnormal (100–
150 ng/mL) or toxic (N150 ng/mL). Mean change was noted at an increase of 37.3±22 ng/mL in the 2-week period (pb0.001). Pre and
peripubertal individuals had a significantly greater increase in 25-OH D levels.
The results of this study demonstrate that very high dosing of vitamin D using oral ergocalciferol over a 14 day period is an effective strategy in
achieving therapeutic levels of 25-OH vitamin D in children and young adults with CF. We believe this regimen deserves further study.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Vitamin D deficiency; Cystic fibrosis; Ergocalciferol1. Introduction
Vitamin D deficiency is found in 10–80% of individuals
with cystic fibrosis (CF) depending on the definition used [1,2].
Supplementation of vitamin D in these patients is done using
ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in
increased doses [3]. Obtaining therapeutic vitamin D levels has
been largely unsuccessful in adults with CF using oral high dose
ergocalciferol (400,000 IU over 2 months) as currently⁎ Corresponding authors. Department of Pediatrics, Evanston Hospital, 2650
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doi:10.1016/j.jcf.2009.04.004recommended [4]. In a recent prospective study using a very
high dose ergocalciferol regimen (1,400,000 IU over 4 weeks),
therapeutic vitamin D levels were achieved in 38 of 56 (68%) of
adults with CF without evidence of vitamin D toxicity
(hypercalcemia) [5]. In a recent retrospective study, an
intervention involving the reinforcement of compliance with
cholecalciferol intake (mean dose 647±339 IU) resulted in a
significant increase in vitamin D levels in 92% of patients [6].
Data in non-CF populations suggest that higher doses of
ergocalciferol are required when compared with cholecalciferol
to correct vitamin D deficiency [6].
The purpose of this study was to evaluate the safety and
efficacy of a 2 week very high dose vitamin D repletion strategy
in children and young adults with CF. We hypothesized that ad by Elsevier B.V. All rights reserved.
Fig. 1. Pre and post vitamin D levels.
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daily) would be an effective treatment for achieving therapeutic
levels of 25-hydroxy (25-OH) vitamin D in a group of children
and young adults with CF.
2. Methods
As part of a quality improvement initiative, a prospective
cohort study was performed from January through April of 2007
at The Cystic Fibrosis Center of Chicago. Phase I included
querying the CF practice database to identify patients who were
due for annual blood tests or who had recently documented
levels of 25-OH vitamin D that were less than 30 ng/mL. In
phase II, 50,000 IU of daily ergocalciferol was prescribed for a
14 day period as part of routine care. During phase III, a post
treatment 25-OH vitamin D level was obtained 3–4 days after
completion of phase II. Compliance was documented by
history.
Baseline subject characteristics were obtained at entry and
included age, weight percentile, body mass index percentile,
gender, pubertal status, and lung status (FEV1% of predicted).
Pubertal status was reported as pre and peri pubertal (Tanner
stages 1–3) and postpubertal (Tanner stages 4, 5).
All 25-OH vitamin D levels were measured using commer-
cially available assays. Post treatment 25-OH vitamin D levels
were classified as sub therapeutic (b30 ng/mL), therapeutic
(30–50 ng/mL), high therapeutic (50–100 ng/mL) and
potentially toxic (N100 ng/mL).
A paired t test was performed to evaluate pre and post
intervention differences. The impact of age, gender and lung
function on the response to vitamin D supplementation was also
analyzed by linear regression. All values were expressed as
mean±standard deviation. Statistical significance was set at
pb0.05.
3. Results
Eighteen patients were studied. The mean age was 16.9 years
(range 6–25 years). Sixty seven percent were males. All 18
patients were pancreatic insufficient and received enzymesupplementation. Weight percentile and body mass index
percentile were 39.0±29.3 and 34.3±32.5 respectively. Base-
line FEV1 (percent of predicted) was 64.9±26.4. Six partici-
pants were pre or peripubertal and 12 were postpubertal.
Response to vitaminD therapy is presented in Fig. 1. Seventeen
of 18 (94%) subjects demonstrated a significant increase in 25-OH
vitaminD levels (mean change 37.3±22 ng/mL, pb0.001; percent
change 214.7±180). All 25-OH vitamin D levels were in the
therapeutic or high therapeutic range without any potentially toxic
levels noted.
There was a statistically significant inverse correlation of
change in 25-OH vitamin D levels with age (r=−0.48, pb0.05).
Pre and peripubertal individuals had a significantly greater
increase in 25-OH vitamin D levels (55.5 ±21.7) than
postpubertal individuals (28.3±16.3; pb0.005).
No statistically significant correlation of change in 25-OH
vitamin D levels with gender, baseline FEV1, and weight or
body mass index percentile was demonstrated.
4. Discussion
Therapeutic 25-OH vitamin D levels were achieved in 17 of
18 children and young adults with CF using this very high dose
ergocalciferol repletion strategy in this study without toxicity.
In a survey of CF treatment centers, Mitchell and colleagues
noted that there was considerable variability in vitamin D
supplementation protocols in patients with low 25-OH
vitamin D levels; only 39% of respondents were following the
CF consensus guidelines for ages 5 years and above [7].
Previous studies in adult CF patients using the CF consensus
guidelines have failed to demonstrate therapeutic efficacy; more
recent investigations in which other high or very high dose
ergocalciferol regimens have yielded mixed results [4,5].
Prestridge and colleagues have designed a treatment algorithm
which resulted in vitamin D levels of ≥30 ng/mL in 70% of
pediatric CF patients [8].
Investigators have noted lower 25-OH vitamin D levels in
adolescents [2]. We demonstrated a significant inverse correla-
tion of change in 25-OH vitamin D levels with age in this group
of patients. In addition, pre and peripubertal individuals had
statistically significantly greater increase in vitamin D levels
than postpubertal individuals in our study. The reasons for these
findings remain to be defined.
A safe and effective repletion regimen is an important
component for maintenance of vitamin D sufficiency and bone
health in children and adults with CF. This very high dose
regimen of vitamin D supplementation appears to be worthy of
further clinical investigation.
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